| Name | Anew Healthcare |
|---|---|
| Location | 412 E Walnut St, Nortonville, Kansas |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 45 |
| Occupancy Rate | 62% |
| Medicare ID (CCN) | 175323 |
| Legal Business Name | Anew Healthcare Operations, Llc |
| Ownership Type | Government - State |
| NPI Number | 1235604752 |
| Organization Name | NORTONVILLE HEALTHCARE LLC |
| Address | 412 Walnut St, Nortonville, KS 66060 |
| Phone Number | 913-886-6400 |
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago
| NPI Number | 1639788524 |
| Organization Name | ANEW HEALTHCARE, LLC |
| Address | 412 E Walnut St, Nortonville, KS 66060 |
| Phone Number | 913-886-6400 |
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago
| NPI Number | 1770560856 |
| Organization Name | VILLAGE VILLA, INC. |
| Address | 412 E Walnut St, Nortonville, KS 66060 |
| Phone Number | 913-886-6400 |
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago
| NPI Number | 1972113256 |
| Organization Name | ANEW HEALTHCARE OPERATIONS, LLC |
| Address | 412 E Walnut St, Nortonville, KS 66060 |
| Phone Number | 913-886-6400 |
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $1300 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.47 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.26 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.34 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.33 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.8 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 31.73 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.74 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 80 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.63 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 11.46 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.63 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 19.61 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 15.38 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 94.78 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 53.24 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 37.35 | 82.93 |
News Archive
Intellectual property officials in South Africa have made history in a landmark decision to award a patent that names an artificial intelligence as the inventor.
Minerva Biotechnologies, a leading cancer and stem cell development company today announced a major breakthrough in human stem cell research.
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.
PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.
› Verified 1 days ago